29 August 2012The development of a single-dose anti-malarial drug by the University of Cape Town (UCT) could help Africa and the rest of the world tackle a disease which claims almost a million lives a year, Minister of Science and Technology Naledi Pandor said on Tuesday.The new molecule, developed by UCT’s Drug Discovery and Development Centre (H3-D), was selected last month by Switzerland’s Medicines for Malaria Venture (MMV) for further development.It will now undergo a lengthy period of clinical trials and has the potential to become a single-dose cure for all strains of malaria and might also be able to block person-to-person transmission of the parasite.Pandor said the compound has already been found to be a complete cure for animals infected by malaria. The department had provided R25-million in funding for the development of the drug.African researchers finding solutionsThe development of the drug has also helped train 10 local scientists and helped cement relations with international partner the MMV, which is based in Switzerland.Pandor lauded the research partnership between the MMV and the H3-D centre and said it was essential to see African researchers involved in finding solutions to African problems.She said South Africa had recently made significant progress in developing the basic sciences that underpin infectious disease research in the fields of immunology, virology, bio-chemistry, microbiology and genetics.With the majority of the more than a billion people infected by communicable diseases located in developing countries, new research into neglected diseases was crucial, Pandor said.The director of H3-D, Kelly Chibale, said the new drug was important, especially as others had proved ineffective in tackling parasites that had become drug-resistant.“When we tested this molecule in animals that are infected with parasites, with a single low dose of this molecule, we could cure the infection completely,” Chibale said.‘A unique research initiative’The H3-D team – with help from the Swiss Tropical and Public Health Institute, Australia’s Centre for Drug Candidate Optimisation and India’s Syngene – spent 18 months developing a candidate molecule suitable for pre-clinical development.Chibale commended the Science and Technology Department for its research chairs initiative, saying his research chair had afforded him the time to put together a team to carry out the research into an anti-malaria drug and was geared to training the next generation of researchers.“This is not something that would have happened if I had been carrying a heavy load of teaching commitments and I think this is something unique and special about this country [the research chairs initiative],” he said.The MMV’s chief scientific officer, Tim Wells, said that if all went well, the drug could expect to hit the market by 2020. He added that the clinical development phase would take around seven years – costing about R20-million a year.He said the aim was to make it available to ordinary Africans, at affordable rates of less than a dollar a dose.Wells added that although a vaccine for African malaria was being developed for 2015, there would still be a need for medication in a drug form.Source: SANews.gov.za
Smash hit? Tesla suffers broken glass mishap at launch of new truck PLAY LIST 01:08Smash hit? Tesla suffers broken glass mishap at launch of new truck00:50Trending Articles02:34Google unveils motion-sensing Pixel 401:37Protesters burn down Iran consulate in Najaf01:47Panelo casts doubts on Robredo’s drug war ‘discoveries’01:29Police teams find crossbows, bows in HK university01:35Panelo suggests discounted SEA Games tickets for students02:49Robredo: True leaders perform well despite having ‘uninspiring’ boss02:42PH underwater hockey team aims to make waves in SEA Games NLEX, which bounced back from its first loss in style last week, tries to get another winning streak going and put its retooled roster to the test yet again when the Road Warriors clash with Blackwater in the PBA Governors’ Cup eliminations at Smart Araneta Coliseum on Friday.ADVERTISEMENT Read Next LATEST STORIES Change of heart on the SEAG SEA Games in Calabarzon safe, secure – Solcom chief Don’t miss out on the latest news and information. UPLB exempted from SEA Games class suspension Catriona Gray spends Thanksgiving by preparing meals for people with illnesses MOST READ Flags of SEA Games countries raised at Athletes Village Brace for potentially devastating typhoon approaching PH – NDRRMC WATCH: Streetboys show off slick dance moves in Vhong Navarro’s wedding LOOK: Venues for 2019 SEA Games Game time is 7 p.m. with the Road Warriors hoping to inch closer to the first quarterfinal slot even as Phoenix Petroleum tries to stop the bleeding when it battles Meralco in the 4:15 p.m. game.Cyrus Baguio plays his first game reunited with old mentor Yeng Guiao at NLEX.FEATURED STORIESSPORTSWATCH: Drones light up sky in final leg of SEA Games torch runSPORTSSEA Games: Philippines picks up 1st win in men’s water poloSPORTSMalditas save PH from shutoutBlackwater, meanwhile, will not be easy pickings as the Elite got a much needed shot in the arm the last time up when Henry Walker arrived and led them to their first win.The Bolts, meanwhile, try to regroup after being dealt a first loss by the Road Warriors. View comments Man sworn in as lawyer by judge who sentenced him to prison as a teen 20 years ago
TagsTransfersAbout the authorPaul VegasShare the loveHave your say Zenit midfielder Leandro Paredes agrees Chelsea contract termsby Paul Vegas9 months agoSend to a friendShare the loveZenit St Petersburg midfielder Leandro Paredes has agreed terms, it has been revealed.Chelsea boss Maurizio Sarri, after victory over Newcastle United on Saturday, declared he wanted to see a replacement for Cesc Fabregas after his departure for AS Monaco.Gazzetta dello Sport says Paredes has been lined up by the Blues and already settled personal terms.Now Chelsea must reach an agreement with Zenit over a fee for the Argentine.An opening offer of £27m has already been lodged.